Session Information

WCLC 2017

18th World Conference on Lung Cancer

Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan

Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.
Presentation Date(s):
- Oct 15 - 18, 2017
- Total Presentations: 2295
Register to Attend WCLC Return to WCLC 2017 Website Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Saturday
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18

Filter Results:

Show Only CME Accredited Sessions

18982

+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
- 22310
  
  +
  
  JCSE 01.18 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
  
  11:30 - 11:30 | Presenter: Yun Fan | Author(s): K. Chen, X. Yu, H. Wang, Z. Huang, Y. Xu, L. Gong
  Abstract
  
  Loading...
20152

+
P1.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- 22562
  
  +
  
  P1.03-007 - A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Xiao Hu | Author(s): Y. Jin, M. Chen, Y. Chen, X. Shi, X. Yu
  Abstract
  
  Loading...
18973

+
P2.01 - Advanced NSCLC
- 09:00 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- 23180
  
  +
  
  P2.01-057 - Activity of Pemetrexed on Wild-Type and Unknown Status EGFR Genes with Brain Metastases from Non-Small Cell Lung Cancer
  
  09:00 - 09:00 | Presenter: Yun Fan | Author(s): X. Yu
  Abstract
  
  Loading...
20167

+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- 23284
  
  +
  
  P2.03-013 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
  
  09:30 - 09:30 | Presenter: Yun Fan | Author(s): K. Chen, X. Yu, H. Wang, Z. Huang, Y. Xu, L. Gong
  Abstract
  
  Loading...
18975

+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- 23886
  
  +
  
  P3.01-027 - TET2 Mutation as a Novel Mechanism of Acquired Resistance to EGFR TKIs Identified by a Mutational Profiling Using NGS
  
  09:30 - 09:30 | Presenter: Xiao Hu | Author(s): Y. Jin, M. Chen, X. Yu
  Abstract
  
  Loading...
- 23928
  
  +
  
  P3.01-069 - Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases
  
  09:30 - 09:30 | Presenter: Yun Fan | Author(s): X. Yu, H. Wang
  Abstract
  
  Loading...

Session Information

WCLC 2017

18th World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West

+

JCSE 01.18 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

+

P1.03 - Chemotherapy/Targeted Therapy

+

P1.03-007 - A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer

+

P2.01 - Advanced NSCLC

+

P2.01-057 - Activity of Pemetrexed on Wild-Type and Unknown Status EGFR Genes with Brain Metastases from Non-Small Cell Lung Cancer

+

P2.03 - Chemotherapy/Targeted Therapy

+

P2.03-013 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

+

P3.01 - Advanced NSCLC

+

P3.01-027 - TET2 Mutation as a Novel Mechanism of Acquired Resistance to EGFR TKIs Identified by a Mutational Profiling Using NGS

+

P3.01-069 - Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases

Stay Connected